Urinary microbiome and metabolomic profiling reveal propionic acid as an enhancer of BCG immunotherapy in bladder cancer
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · 2026-04 · 1872 (4) · 168192
DOI: 10.1016/j.bbadis.2026.168192 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2026-04. Verfasst von Jing Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China; School…. Hauptthemen laut MEDLINE: Propionates, Urinary Bladder Neoplasms, Microbiota, BCG Vaccine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
Bladder cancer (BC) is the tenth most common malignancy worldwide, with non-muscle invasive bladder cancer (NMIBC) accounting for approximately 75% of cases, and Bacillus Calmette-Guérin (BCG) remaining the standard intravesical therapy. In light of global BCG shortages, this study aimed to identify potential strategies to enhance BCG efficacy by integrating urinary microbiome profiling with targeted short-chain fatty acid (SCFA) metabolomics. Urine samples collected from BC patients before and after BCG instillation were analyzed to determine BCG-associated microbial and metabolic changes, and the functional role of the key metabolite propionic acid (PA) was evaluated through in vitro experiments using MB49 and MBT2 murine BC cell lines and in vivo mouse BC models treated with BCG plus PA. Flow cytometry was used to quantify tumor-infiltrating CD4+ and CD8+ T cells to elucidate immune-related mechanisms. BCG treatment significantly reshaped urinary microbial composition, dominant flora, and fatty acid metabolic patterns, and notably increased urinary PA levels. Functional assays demonstrated that PA markedly augmented the antitumor activity of BCG, potentially by promoting CD4+/CD8+ T-cell infiltration into tumor tissues. Collectively, these findings indicate that BCG modulates the urinary microbiome and SCFA metabolic landscape in BC patients, and that PA enhances BCG efficacy by boosting T-cell-mediated immune responses, highlighting PA-BCG combination therapy as a promising therapeutic strategy for BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China; School of Medicine, University of Electronic Science and Technology of China…
- Department of Pharmacy, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China; School of Medicine, University of Electronic Science and Technology of Chin…
- Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China; School of Medicine, University of Electronic Science and Technol…
Förderung
- Science and Technology Department of Sichuan Province
Zitieren
APA
Liu, J., Luo, Y., Chen, L., Xiong, W., An, Y., Ma, Z., & Zhang, D. (2026). Urinary microbiome and metabolomic profiling reveal propionic acid as an enhancer of BCG immunotherapy in bladder cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1872(4), 168192. https://doi.org/10.1016/j.bbadis.2026.168192
Vancouver
Liu J, Luo Y, Chen L, Xiong W, An Y, Ma Z, et al. Urinary microbiome and metabolomic profiling reveal propionic acid as an enhancer of BCG immunotherapy in bladder cancer. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2026;1872(4):168192. doi:10.1016/j.bbadis.2026.168192
BibTeX
@article{Liu2026,
author = {Liu, Jing and Luo, Yizhao and Chen, Lu and Xiong, Wei and An, Yu and Ma, Zhiwei and Zhang, Dan},
title = {Urinary microbiome and metabolomic profiling reveal propionic acid as an enhancer of BCG immunotherapy in bladder cancer},
journal = {Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease},
year = {2026},
volume = {1872},
number = {4},
pages = {168192},
doi = {10.1016/j.bbadis.2026.168192}
}
EUVIMED